Transport and assembly of gag proteins into moloney murine leukemia virus

Mark Hansen, Laura Jelinek, Sam Whiting, Eric Barklis

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

We have studied the process of Moloney murine leukemia virus (M-MuLV) assembly by characterization of core (gag) protein mutants and analysis of wild-type (wt) gag proteins produced by cells in the presence of the ionophore monensin. Our genetic studies involved examination of linker insertion mutants of a Gag-β-galactosidase (Gag-β-gal) fusion protein, GBG2051, which is incorporated into virus particles when expressed in the presence of wt viral proteins. Analysis indicated that the amino-terminal two-thirds of the gag matrix domain is essential for targeting of proteins to the plasma membrane; mutant proteins localized to the cytoplasm or were trapped on intracellular membranes. Mutations through most of the coding region of the gag capsid domain generated proteins which were released from cells in membrane vesicles but not in virions. In contrast, linker insertions into p12gag or carboxy-terminal portions of the matrix or capsid coding regions did not affect assembly of fusion proteins into virus particles. Monensin, which blocks vesicular transport, inhibited gag protein intracellular transport and release from cells. Our results suggest that a significant proportion of M-MuLV myristylated gag proteins travel via vesicles to the cell surface. Specific matrix protein polypeptide regions and myristic acid modification are both necessary for appropriate gag protein transport, while capsid protein interactions appear to mediate the final phase of virion formation.

Original languageEnglish (US)
Pages (from-to)5306-5316
Number of pages11
JournalJournal of Virology
Volume64
Issue number11
StatePublished - 1990

Fingerprint

Murine leukemia virus
Moloney murine leukemia virus
gag Gene Products
Virion
Protein Transport
Monensin
Capsid
virion
proteins
Cell Membrane
Galactosidases
Virus Assembly
Intracellular Membranes
Proteins
capsid
monensin
Ionophores
Myristic Acid
Capsid Proteins
Viral Proteins

ASJC Scopus subject areas

  • Immunology

Cite this

Transport and assembly of gag proteins into moloney murine leukemia virus. / Hansen, Mark; Jelinek, Laura; Whiting, Sam; Barklis, Eric.

In: Journal of Virology, Vol. 64, No. 11, 1990, p. 5306-5316.

Research output: Contribution to journalArticle

Hansen, M, Jelinek, L, Whiting, S & Barklis, E 1990, 'Transport and assembly of gag proteins into moloney murine leukemia virus', Journal of Virology, vol. 64, no. 11, pp. 5306-5316.
Hansen, Mark ; Jelinek, Laura ; Whiting, Sam ; Barklis, Eric. / Transport and assembly of gag proteins into moloney murine leukemia virus. In: Journal of Virology. 1990 ; Vol. 64, No. 11. pp. 5306-5316.
@article{49fe3be32aa44fbe88785fa48933266f,
title = "Transport and assembly of gag proteins into moloney murine leukemia virus",
abstract = "We have studied the process of Moloney murine leukemia virus (M-MuLV) assembly by characterization of core (gag) protein mutants and analysis of wild-type (wt) gag proteins produced by cells in the presence of the ionophore monensin. Our genetic studies involved examination of linker insertion mutants of a Gag-β-galactosidase (Gag-β-gal) fusion protein, GBG2051, which is incorporated into virus particles when expressed in the presence of wt viral proteins. Analysis indicated that the amino-terminal two-thirds of the gag matrix domain is essential for targeting of proteins to the plasma membrane; mutant proteins localized to the cytoplasm or were trapped on intracellular membranes. Mutations through most of the coding region of the gag capsid domain generated proteins which were released from cells in membrane vesicles but not in virions. In contrast, linker insertions into p12gag or carboxy-terminal portions of the matrix or capsid coding regions did not affect assembly of fusion proteins into virus particles. Monensin, which blocks vesicular transport, inhibited gag protein intracellular transport and release from cells. Our results suggest that a significant proportion of M-MuLV myristylated gag proteins travel via vesicles to the cell surface. Specific matrix protein polypeptide regions and myristic acid modification are both necessary for appropriate gag protein transport, while capsid protein interactions appear to mediate the final phase of virion formation.",
author = "Mark Hansen and Laura Jelinek and Sam Whiting and Eric Barklis",
year = "1990",
language = "English (US)",
volume = "64",
pages = "5306--5316",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "11",

}

TY - JOUR

T1 - Transport and assembly of gag proteins into moloney murine leukemia virus

AU - Hansen, Mark

AU - Jelinek, Laura

AU - Whiting, Sam

AU - Barklis, Eric

PY - 1990

Y1 - 1990

N2 - We have studied the process of Moloney murine leukemia virus (M-MuLV) assembly by characterization of core (gag) protein mutants and analysis of wild-type (wt) gag proteins produced by cells in the presence of the ionophore monensin. Our genetic studies involved examination of linker insertion mutants of a Gag-β-galactosidase (Gag-β-gal) fusion protein, GBG2051, which is incorporated into virus particles when expressed in the presence of wt viral proteins. Analysis indicated that the amino-terminal two-thirds of the gag matrix domain is essential for targeting of proteins to the plasma membrane; mutant proteins localized to the cytoplasm or were trapped on intracellular membranes. Mutations through most of the coding region of the gag capsid domain generated proteins which were released from cells in membrane vesicles but not in virions. In contrast, linker insertions into p12gag or carboxy-terminal portions of the matrix or capsid coding regions did not affect assembly of fusion proteins into virus particles. Monensin, which blocks vesicular transport, inhibited gag protein intracellular transport and release from cells. Our results suggest that a significant proportion of M-MuLV myristylated gag proteins travel via vesicles to the cell surface. Specific matrix protein polypeptide regions and myristic acid modification are both necessary for appropriate gag protein transport, while capsid protein interactions appear to mediate the final phase of virion formation.

AB - We have studied the process of Moloney murine leukemia virus (M-MuLV) assembly by characterization of core (gag) protein mutants and analysis of wild-type (wt) gag proteins produced by cells in the presence of the ionophore monensin. Our genetic studies involved examination of linker insertion mutants of a Gag-β-galactosidase (Gag-β-gal) fusion protein, GBG2051, which is incorporated into virus particles when expressed in the presence of wt viral proteins. Analysis indicated that the amino-terminal two-thirds of the gag matrix domain is essential for targeting of proteins to the plasma membrane; mutant proteins localized to the cytoplasm or were trapped on intracellular membranes. Mutations through most of the coding region of the gag capsid domain generated proteins which were released from cells in membrane vesicles but not in virions. In contrast, linker insertions into p12gag or carboxy-terminal portions of the matrix or capsid coding regions did not affect assembly of fusion proteins into virus particles. Monensin, which blocks vesicular transport, inhibited gag protein intracellular transport and release from cells. Our results suggest that a significant proportion of M-MuLV myristylated gag proteins travel via vesicles to the cell surface. Specific matrix protein polypeptide regions and myristic acid modification are both necessary for appropriate gag protein transport, while capsid protein interactions appear to mediate the final phase of virion formation.

UR - http://www.scopus.com/inward/record.url?scp=0025183715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025183715&partnerID=8YFLogxK

M3 - Article

C2 - 1698996

AN - SCOPUS:0025183715

VL - 64

SP - 5306

EP - 5316

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 11

ER -